Literature DB >> 22405481

Detection and disposition of JWH-018 and JWH-073 in mice after exposure to "Magic Gold" smoke.

Justin L Poklis1, Dorra Amira, Laura E Wise, Jason M Wiebelhaus, Brenda J Haggerty, Alphonse Poklis.   

Abstract

The disposition in mice of the cannabimimetics JWH-018 and JWH-073 in blood and brain following inhalation of the smoke from the herbal incense product (HIP) "Magic Gold" containing 3.6% JWH-018, 5.7% JWH-073 and less than 0.1% JWH-398 (w/w) is presented. Specimens were analyzed by HPLC/MS/MS. The validation of the method is also presented. Five C57BL6 mice were sacrificed 20 min after exposure to the smoke of 200 mg of "Magic Gold" and a second set of five exposed mice were sacrificed after 20 h. Twenty minutes after exposure to "Magic Gold" smoke, blood concentrations of JWH-018 ranged from 42 to 160 ng/mL (mean: 88 ng/mL ± 42) and those of JWH-073 ranged from 67 to 244 ng/mL (mean: 134 ng/mL ± 62). Brain concentrations 20 min after exposure to "Magic Gold" smoke for JWH-018 ranged from 225 to 453 ng/g (mean: 317 ng/g ± 81) and those of JWH-073 ranged from 412 to 873 ng/g (mean: 584 ng/g ± 163). Twenty hours after exposure to "Magic Gold" smoke, JWH-018 was detected and quantified in only two of the five blood samples. Blood concentrations of JWH-018 were 3.4 ng/mL and 9.4 ng/mL. JWH-073 was detected in only one blood specimen 20 h after exposure at 4.3 ng/mL. Brain concentrations 20 h post exposure for JWH-018 ranged from 7 to 32 ng/g (mean: 19 ng/g ± 9). JWH-073 was not detected in 20 h post exposure brain specimens. JWH-398 was not detected in any of the blood or brain samples. The disposition data presented with the limited data available from human experience provide reasonable expectations for forensic toxicologists in JWH-018 or JWH-073 cases. As with THC after smoking marijuana, blood and brain concentrations of JWH-018 and JWH-073 after HIP smoking can be expected to rise initially to readily detected values, and then drop dramatically over the next few hours to several ng/mL or ng/g, and finally to be at extremely low or undetectable concentrations by 24h apparently due to extensive biotransformation, and redistribution to body fat.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405481      PMCID: PMC3677765          DOI: 10.1016/j.forsciint.2012.02.003

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  25 in total

1.  Identification of a cannabinoid analog as a new type of designer drug in a herbal product.

Authors:  Nahoko Uchiyama; Ruri Kikura-Hanajiri; Nobuo Kawahara; Yuji Haishima; Yukihiro Goda
Journal:  Chem Pharm Bull (Tokyo)       Date:  2009-04       Impact factor: 1.645

2.  Chromatography-mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures.

Authors:  Andrej Grigoryev; Sergey Savchuk; Aleksandra Melnik; Natal'ja Moskaleva; Jurij Dzhurko; Mihail Ershov; Aleksandr Nosyrev; Aleksandr Vedenin; Boris Izotov; Irina Zabirova; Vladimir Rozhanets
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-03-26       Impact factor: 3.205

3.  The pharmacological activity of inhalation exposure to marijuana smoke in mice.

Authors:  A H Lichtman; J L Poklis; A Poklis; D M Wilson; B R Martin
Journal:  Drug Alcohol Depend       Date:  2001-07-01       Impact factor: 4.492

4.  Chemical analysis of synthetic cannabinoids as designer drugs in herbal products.

Authors:  Nahoko Uchiyama; Ruri Kikura-Hanajiri; Jun Ogata; Yukihiro Goda
Journal:  Forensic Sci Int       Date:  2010-05-20       Impact factor: 2.395

5.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

6.  Disposition of cannabichromene, cannabidiol, and Δ⁹-tetrahydrocannabinol and its metabolites in mouse brain following marijuana inhalation determined by high-performance liquid chromatography-tandem mass spectrometry.

Authors:  Justin L Poklis; Candace C Thompson; Kelly A Long; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2010-10       Impact factor: 3.367

7.  Pharmacology and stereoselectivity of structurally novel cannabinoids in mice.

Authors:  P J Little; D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

8.  Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol.

Authors:  A Weissman; G M Milne; L S Melvin
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

9.  Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents.

Authors:  D R Compton; M R Johnson; L S Melvin; B R Martin
Journal:  J Pharmacol Exp Ther       Date:  1992-01       Impact factor: 4.030

10.  Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry.

Authors:  R L Foltz; K M McGinnis; D M Chinn
Journal:  Biomed Mass Spectrom       Date:  1983-05
View more
  8 in total

1.  Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Authors:  Jason M Wiebelhaus; Justin L Poklis; Alphonse Poklis; Robert E Vann; Aron H Lichtman; Laura E Wise
Journal:  Drug Alcohol Depend       Date:  2012-07-07       Impact factor: 4.492

2.  Behavioral responses to acute and sub-chronic administration of the synthetic cannabinoid JWH-018 in adult mice prenatally exposed to corticosterone.

Authors:  Simone Macrì; Lara Lanuzza; Gustavo Merola; Chiara Ceci; Stefano Gentili; Antonella Valli; Teodora Macchia; Giovanni Laviola
Journal:  Neurotox Res       Date:  2013-01-08       Impact factor: 3.911

3.  Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073.

Authors:  Ziva D Cooper; Justin L Poklis; Fei Liu
Journal:  Neuropharmacology       Date:  2017-11-14       Impact factor: 5.250

4.  Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain.

Authors:  Kimberly L Samano; Justin L Poklis; Aron H Lichtman; Alphonse Poklis
Journal:  J Anal Toxicol       Date:  2014-05-09       Impact factor: 3.367

Review 5.  Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization.

Authors:  Delphine Psychoyos; K Yaragudri Vinod
Journal:  Drug Test Anal       Date:  2012-08-13       Impact factor: 3.345

6.  Distribution of Synthetic Cannabinoids JWH-210, RCS-4 and Δ 9-Tetrahydrocannabinol After Intravenous Administration to Pigs.

Authors:  Nadine Schaefer; Mattias Kettner; Matthias W Laschke; Julia Schlote; Andreas H Ewald; Michael D Menger; Hans H Maurer; Peter H Schmidt
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 7.  Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy.

Authors:  Bogdan Ionel Tamba; Gabriela Dumitrita Stanciu; Cristina Mariana Urîtu; Elena Rezus; Raluca Stefanescu; Cosmin Teodor Mihai; Andrei Luca; Gabriela Rusu-Zota; Maria-Magdalena Leon-Constantin; Elena Cojocaru; Bogdan Gafton; Teodora Alexa-Stratulat
Journal:  Medicina (Kaunas)       Date:  2020-01-09       Impact factor: 2.430

8.  Is adipose tissue suitable for detection of (synthetic) cannabinoids? A comparative study analyzing antemortem and postmortem specimens following pulmonary administration of JWH-210, RCS-4, as well as ∆9-tetrahydrocannabinol to pigs.

Authors:  Nadine Schaefer; Frederike Nordmeier; Ann-Katrin Kröll; Christina Körbel; Matthias W Laschke; Michael D Menger; Hans H Maurer; Markus R Meyer; Peter H Schmidt
Journal:  Arch Toxicol       Date:  2020-07-14       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.